News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

N-of-One Selected To Provide Scalable Clinical Data For Cedars-Sinai Medical Center Cancer Patients

4/30/2014 11:19:09 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LEXINGTON, Mass., April 30, 2014 – N-of-One, Inc., the leading provider of clinical interpretation in oncology, today announced that the company is providing Cedars-Sinai’s Samuel Oschin Comprehensive Cancer Institute in Los Angeles with database services for next-generation sequencing.

“We are pleased to provide a database of genetic information to the team of physicians and scientists at Cedars-Sinai and to support their ability to provide clinical pathological integration to deliver cutting-edge diagnostic and treatment options to their patients,” said Chris Cournoyer, CEO of N-of-One. “We are helping leading cancer centers link to the knowledge of therapeutic options in a scalable, cost-effective way.”

Cedars-Sinai joins a growing number of leading cancer centers that are building internal genetic sequencing programs for precision oncology.

“By combining next-generation sequencing with our research and clinical expertise at Cedars-Sinai, we can now truly deliver on the promise of precision medicine,” said Steven Piantadosi, MD, PhD, director of the Samuel Oschin Comprehensive Cancer Institute and the Phase One Foundation Chair. “Patients will benefit from a broader range of treatment options, including investigational, molecular-guided therapies that are based on the individual makeup of their given tumor.”

Cedars-Sinai’s Department of Pathology and Laboratory Medicine was recently named the 2014 Lab of the Year by Medical Laboratory Observer for its commitment to quality patient care, from employing new technologies including next-generation sequencing, to embracing opportunities to serve the local community.

N-of-One, a leader in precision medicine for oncology, leverages its world-class team of experts to translate molecular data specific to each patient into state-of-the-art, clinical insights and therapeutic options. N-of-One’s team of experts has interpreted more than 7,000 tumors for oncologists and patients worldwide, through partnerships to provide clinical interpretation for leading diagnostic companies (such as Foundation Medicine and Clarient), through agreements with provider networks (such as Fox Chase Cancer Center in Philadelphia), directly to oncologists and through employee access benefit programs (such as Life Technologies). N-of-One does not provide medical advice or promote any product or service. For more information, please visit or call 617-202-9808.

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus